Intracerebral hemorrhage (ICH) holds a particularly prominent place in this year’s programme, with dedicated sessions, clinical trials, and innovative approaches spanning imaging, pathophysiology, and brain repair.
This is a crucial recognition for a condition that still too often lacks disease‑specific therapeutic solutions.
The TIPITCH RHU is proud to actively contribute to this momentum, with numerous presentations delivered by members of the consortium:
🔹 Prof. Charlotte Cordonnier (CHU de Lille)
• ESOC TV – Large Clinical Trials: implications for clinical practice
• Microcirculatory dysfunction in intracerebral hemorrhage
🔹 Dr Laurent Puy (Lille University Hospital)
• Can we stimulate haematoma clearance and repair mechanisms after ICH?
🔹 Dr Quentin Beaufort (PhD, Tours University Hospital)
• Non‑invasive exclusion of arteriovenous shunts in ICH using MRI arterial spin labelling
🔹 Prof. Marco Pasi (CHRU de Tours)
• Clinical relevance of cerebral amyloid angiopathy in acute stroke reperfusion therapies
🔹 Dr Valentin Amar (PhD, Tours University Hospital)
• Poster – Cognitive and neuroimaging profile of sporadic cerebral amyloid angiopathy patients with phosphorylated TAU positivity
Ahead of the main congress, the ICH Academy Meeting will take place on May 5, an international scientific event dedicated to ICH research, featuring contributions from Dr Valentin Amar, Dr Maxime Baudouin, and Dr Quentin Beaufort, PhD candidates within the TIPITCH project.
Thank you to the European Stroke Organisation for the prominent place given to ICH at ESOC 2026, and congratulations to all clinician‑scientists committed to advancing research in this still underexplored field.
Inauguration of the 7‑Tesla MRI at Lille University Hospital: a major step forward for TIPITCH
On 28 April, Lille University Hospital (CHU de Lille), lead institution of the RHU TIPITCH project, inaugurated its 7‑Tesla MRI scanner—an exceptional piece of equipment opening up unprecedented opportunities for clinical research in neuroscience and neurovascular diseases.
This ultra‑high‑resolution imaging technology represents a major strategic asset for the TIPITCH project – Transforming the prognosis of haemorrhagic stroke.
A key lever to better understand haemorrhagic stroke
Within TIPITCH, the 7T MRI will be used to:
🔹 Identify new imaging biomarkers of peri‑haematomal oedema following intracerebral haemorrhage
🔹 Improve the identification of patients at risk of severe disease progression
🔹 Refine predictions of functional outcome, a central challenge for personalised patient care
The ambition: to enhance anticipation and clinical decision‑making through ultra‑high‑precision imaging.
- Prof Grégory Kuchcinski
- Dr Renaud Lopes
What’s next?
First TIPITCH patient inclusions: before summer 2026
This inauguration fully illustrates the CHU de Lille’s ability to bring together cutting‑edge infrastructure, clinical excellence and translational research, all in the service of patients affected by haemorrhagic stroke.
To learn more about the 7‑Tesla MRI at Lille University Hospital: ARIANES : mise en réseaux des IRM 3 Tesla
Regional victory for Guillaume RENEDO: heading to the national final!
Double distinction:
➡️ First Prize – Jury Award
➡️ Audience Award
Thanks to this outstanding performance, Guillaume will represent Nouvelle‑Aquitaine at the national final, which will take place in Lille on 28 May 2026.
A demanding PhD topic, explained with clarity and conviction
Among 18 PhD candidates from higher education institutions across the region, Guillaume stood out for the quality, pedagogy and accessibility of his presentation, focusing on his PhD research:
“Numerical simulation of intraparenchymal haemorrhage: from in silico modelling to the development of an innovative endovascular device.”
This work lies at the very heart of the ambitions of the TIPITCH project, combining numerical modelling, technological innovation and clinical challenges related to haemorrhagic stroke.
Onwards to the national final
This qualification marks entry into the final stage of a high‑level science communication competition, where Guillaume will proudly represent his region, his field of research and French translational research on the national stage.
Watch the national final live:
https://lnkd.in/eRtS3pke
The entire TIPITCH community warmly congratulates Guillaume and wishes him every success for the national final in Lille.
Congratulations Guillaume on this inspiring achievement, which perfectly illustrates the commitment and talent of our Pitchous!
On the occasion of World Haemophilia Day, the RHU TIPITCH project would like to highlight a population that is still too often excluded from clinical studies: patients at high haemorrhagic risk.
This includes in particular:
- people living with haemophilia or other genetic coagulation disorders,
- as well as certain patients receiving anticoagulant therapy.
Although these profiles account for around 15% of intracerebral haemorrhages, they have historically been under‑represented in research, due to the complexity and risks involved.
TIPITCH: addressing this challenge head‑on
Within RHU TIPITCH, a dedicated work package (WP2) directly tackles this issue.
Its objective is to better understand haematoma formation in these specific contexts and to safely promote haematoma evacuation in the patients at highest risk.
To achieve this, the teams:
- use blood samples to model haematomas in the laboratory,
- analyse the biological mechanisms specific to these patients,
- and test innovative approaches, with the aim of developing safer and more appropriate treatments.
A major milestone reached
A key step has recently been achieved: the clinical trial arising from this work began on 2 March.
Since its launch, 40 participants have already been included, clearly illustrating the project’s inclusive ambition:
- 1 healthy volunteer
- 10 patients receiving anticoagulant therapy
- 20 patients receiving antiplatelet therapy
- 3 patients with von Willebrand disease
- 6 patients with haemophilia (3 with haemophilia A and 3 with haemophilia B)
These are profiles that have historically been excluded from clinical trials and are now fully integrated into research — marking a tangible step towards truly inclusive medicine.
Also worth (re)discovering
Our video “TIPITCH in 2 minutes”, in which Prof Annabelle Dupont (Lille University Hospital) presents this key module, co‑led with Prof Sophie Susen, and outlines the foundations of this innovative therapeutic strategy.
On this World Haemophilia Day, TIPITCH reaffirms a strong conviction:
research must also — and above all — address the needs of the most vulnerable patients.
The JNLF 2026 officially opened yesterday in Marseille, bringing together the neurological community to discuss major advances in the field.
This afternoon (3:00–4:15 pm), a session dedicated to intracerebral haemorrhage will highlight key clinical and scientific issues central to neurological practice — a topic at the very heart of the RHU TIPITCH project.
Speakers include:
- Prof Marco Pasi (Tours University Hospital)
“The ICH Checklist: new approaches to the management of intracerebral haemorrhage” - Prof Charlotte Cordonnier (Lille University Hospital)
Long‑term complications following intracerebral haemorrhage
Both are members of the TIPITCH project.
These moments of exchange and knowledge sharing are essential for neurology professionals in order to:
➡️ disseminate knowledge,
➡️ compare and discuss clinical practices,
➡️ and collectively improve the care of patients affected by haemorrhagic stroke.
TIPITCH is fully aligned with this dynamic approach, combining clinical research, innovation and knowledge transfer as close as possible to everyday clinical practice.
Wishing everyone a great JNLF 2026!
On March 31, at MAME Tours – the City of Creativity and Innovation, a conference dedicated to post‑stroke care was held, organized by the CHRU of Tours in partnership with the University of Tours and with the support of the TIPITCH project.
This event was a true success in many respects: ◾ the choice of a crucial and still too rarely discussed topic: life after the acute phase of stroke;
◾ a full conference room, reflecting strong interest in the subject;
◾ a wide diversity of participants brought together: healthcare professionals (medical, paramedical, and social care), stroke survivors, caregivers, institutions, patient associations, and citizens engaged with these issues;
◾ and above all, the richness and authenticity of the discussions among women and men committed to continuously improving long‑term care and support for people affected by stroke.
Within the RHU TIPITCH project, we are particularly proud to support this initiative led by the CHRU of Tours, a key project partner and leader of Work Package 4, dedicated to the establishment of a national cohort and the creation of a brain imaging core analysis center.
This event perfectly illustrates an approach that places patients at the heart of both clinical practice and research thinking.
Congratulations to all the teams at the CHRU of Tours and their partners for the high quality of the organization and their collective commitment.
